Roles for SGLT2 Inhibitors in Cardiorenal Disease
This article aims to provide a comprehensive overview of the efficacy of SGLT2i therapy in patients at risk of cardiorenal disease. A literature review of large outcome studies of patients who had CKD or heart failure with reduced ejection fraction (HFrEF, defined as having a left ventricle ejection fraction [LVEF]
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology